Bixiye
QP48-23 Update for New to Market Medical Drugs: delandistrogene moxeparvovec and epcoritamab
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Natiijooyinka Raadinta
Soo bandhiga 1751 - 1760 ee natiijooyinka 4139
Macluumaadka Maaliyadda
Bixiye
commercial-general-coding-016-drug-wastage.pdf
Macluumaadka Maaliyadda
Bixiye
commercial-general-coding-079-hair-removal-for-gender-affirming-procedures.pdf
Bixiye
QP49-23 Register for Webinar | Trauma-Informed Care 101 | Thursday, June 29, 5-6:30 pm
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP50-23 Fetal Alcohol Syndrome Education Opportunity
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP51-23 Commercial Pharmacy Benefit Exclusion for Aponvie™, Iheezo™, Omisirge®, and Qalsody™
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP52-23 MHCP Pharmacy Benefit Exclusion for Iheezo™, Omisirge®, and Qalsody™
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP53-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective August 1, 2023
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP54-23 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective July 1, 2023
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP55-23 Change in Processing for Replacement Claims
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023